Modified risk scoring system for acute exacerbation of interstitial lung disease

Abstract

Background

Lung cancer patients with interstitial lung disease often develop acute exacerbation of their interstitial lung disease after lung resection. Special care is needed in selection of the surgical procedure to reduce acute exacerbation and provide long-term survival.

Methods

The Japanese Association for Chest Surgery devised a risk scoring system based on 7 risk factors to predict the probability of postoperative acute exacerbation. We excluded surgical procedures and used a modified system categorizing 4 groups: group A (risk score 0–6), group B (risk score 7–10), group C (risk score 11–14), and group D (risk score 15–18). We retrospectively examined 60 lung cancer patients with interstitial lung disease to determine whether the modified risk scoring system is useful for selecting the optimal surgical procedure in anticipation of curability and risk of postoperative acute exacerbation.

Results

Eight (13.3%) patients experienced postoperative acute exacerbation. In group A (n = 20), there was no difference in the incidence of acute exacerbation between wedge (0%) and anatomic resection (6.3%, p = 0.800). In group B (n = 40), the incidence was significantly higher after anatomic resection (5.0% vs. 30.0%, p = 0.046). Thus group A had high-quality outcomes with anatomic resection, and in group B, the incidence of postoperative acute exacerbation can be reduced if wedge resection is performed.

Conclusions

Our modified risk scoring can be useful for selecting the optimal surgical procedure in anticipation of curability and the risk of acute exacerbation of interstitial lung disease after lung cancer surgery.

Keywords

Lung diseases interstitial Lung neoplasms Pneumonectomy Postoperative complications Risk factors

Get full access to this article

View all access options for this article.

References

Kumar

Goldstraw

Yamada

et al . Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003; 125: 1321–1327.

Watanabe

Miyajima

Mishina

et al . Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis, Gen Thorac Cardiovasc Surg 2013; 61: 254–261.

Wada

Nakamura

Nakamoto

Maeda

and Watanabe

Thirty-day operative mortality for thoracotomy in lung cancer.

J Thoracic Cardiovasc Surg 1998; 115: 70–73.

Masuda

Kuwano

Okumura

et al . Thoracic and cardiovascular surgery in Japan during 2012: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2014; 62: 734–764.

Chiyo

Sekine

Iwata

et al . Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 2003; 126: 1141–1146.

Koizumi

Hirata

Hirai

et al.

Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg 2004; 10: 340–346.

Watanabe

Kawaharada

and Higami

Postoperative acute exacerbation of IPF after lung resection for primary lung cancer.

Pulm Med 2011; 2011: 960316.

Kondoh

Taniguchi

Kitaichi

et al . Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006; 100: 1753–1759.

Ginsberg

and Rubinstein

LV.

Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Ann Thoracic Surg 1995; 60: 615–622.

10.

Taniguchi

Yamasaki

Miyazaki

et al . The surgical outcomes of lung cancer combined with interstitial pneumonia: a single‑institution report. Surg Today 2017; 47: 1397–1404.

11.

Sato

Teramukai

Kondo

et al . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 2014; 147: 1604–11.e3.

12.

Sato

Kondo

Watanabe

et al . A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 2015; 63: 164–172.

13.

Raghu

Collard

Egan

et al . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–724.

14.

Yoshimura

Nakatani

Nakamori

et al . Acute exacerbation in idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1984; 22: 1012–1020.

15.

Raghu

Nyberg

and Morgan

The epidemiology of interstitial lung disease and its association with lung cancer.

Br J Cancer 2004; 91(Suppl):S3–10.

16.

Minegishi

Takenaka

Mizutani

et al . Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009; 48: 665–672.

17.

Isobe

Hata

Sakamoto

Takai

Shibuya

and Homma

Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy.

Respirology 2010; 15: 88–92.

18.

Yamashita

Kobayashi-Shibata

Terahara

et al . Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010; 5: 32.

19.

Saito

Kawai

Takahashi

et al . Survival after surgery for pathologic stage IA non-small cell cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg 2011; 92: 1812–1817.

20.

Sato

Watanabe

Kondo

et al . Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 2015; 149: 64–9, 70.e1-2.